Scopio’s Complete Blood Morphology (CBM®) ushers in a new era of lab automation, analyzing 10x more cells than the current standard of care in blood cell morphology, addressing global laboratory staffing crisis and accelerating hematology workflows and efficiencies
Scopio Labs, developer of Full-Field Cell Morphology imaging and analysis platform, announced today the unveiling of its groundbreaking Complete Blood Morphology (CBM®) analyzer. CBM will bring unprecedented scale, efficiency and standardization to hematology through autonomous morphology analysis and reporting, one of the last remaining manual processes in diagnostics. To expedite the go-to-market of CBM®, Viola Growth has joined as a new investor with a $10 million extension to Scopio’s Series D funding, bringing the total to $52 million.
While Complete Blood Counts (CBCs) have been automated for decades, laboratories still require a human in the loop during the Peripheral Blood Smear (PBS) review process. PBS review remains labor intensive, complex, and plagued by inefficiencies and variability resulting in bottlenecks that affect turnaround times, scalability, and ultimately, patient care. These issues are amplified given the ongoing staffing crisis in clinical laboratories. Global workforce shortages, long training cycles, and increased demand for diagnostic tests have left labs struggling to maintain performance.
CBM® is built on top of Scopio’s proprietary Full-Field technology, leveraging advanced computational imaging and AI-powered analysis to transform current PBS review workflow into an autonomous, standardized, and clinically relevant process, analyzing 10x more cells than the current standard of care in blood cell morphology. Hematology labs currently utilizing Scopio’s Full-Field PBS platform are already alleviating some of the pain points, while laying the essential groundwork for rapid CBM® adoption, effectively future-proofing their operations.
“Our vision is to be the first to close the automation gap in hematology by developing a fully integrated and automated hematology process from CBC to final result,” said Itai Hayut, CEO and Co-founder at Scopio Labs. “This isn’t just a small step forward, it could potentially reshape the whole market by changing the workflow, the economics, and creating an entirely new market category. With CBM®, the market can evolve from current digital lab solutions that help people make decisions, to a system that’s designed to deliver fully automated results with the goal of eliminating the need for routine human morphology review altogether. Beyond that, we also believe that this technology will pave the way to developing accurate and consistent morphology-based biomarkers and diagnostic panels, which can be used for early detection and monitoring of disease directly from blood.”
“We’re excited to join Scopio on their journey to reshape the future of hematology diagnostics,” said Igal Shany, General Partner at Viola Growth. “Scopio’s CBM® analyzer represents a major leap forward for hematology labs, delivering autonomous morphology review with the depth, speed, and scalability this critical step urgently needs.”
Scopio Labs currently has CE-marked and FDA-cleared digital imaging applications in the market, including applications for peripheral blood smear and bone marrow aspirate analysis.
Scopio will showcase CBM® at the ADLM 2025 Annual Conference in Chicago from July 29-31, Booth #3637
Scopio Labs’ CBM® is under development and not available for in vitro diagnostic use.
Scopio’s Full-Field Bone Marrow Aspirate Application is CE-marked cleared for sales in additional regions. Not commercially available in the US for in vitro diagnostic procedures.
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!